MBX Biosciences reports sustained one-year data for weekly drug trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/28/2026
- Wall Street ends lower after Fed Chair Warsh reaffirms inflation fight
- Fed chair Warsh kicks off Jackson Hole keynote address
- PayPal tumbles as Advent, Stripe said to drop $50 bln pursuit
- Oil settles lower on clues about Fed policy, rumors of Hormuz deal
- Dollar jumps after Warsh comments, set for weekly gain
- First Financial to acquire Hickory Point Bank in $111.3M deal
- Affirm Holdings (AFRM) Tops Q4 EPS by $3.77, Beats on Revenue
- McKesson reports cybersecurity incident affecting its information systems
- Nasdaq, S&P 500 lifted by Nvidia's forecast; investors eye speech by Fed's Warsh
- BioNTech ends colorectal cancer mRNA therapy trial early
MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide as a Potential PTH Replacement Therapy in Chronic Hypoparathyroidism
June 12, 2026 7:00 AM EDTResponder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Phase 2 Avail trial
Results consistent with restoration of systemic PTH activity through serum calcium normalization, reduction of urine calcium excretion, restoration of bone metabolism and increase of eGFR (a measure of kidney function)
High retention rate with 90% of patients entering the OLE remaining in the study at one year
Canvuparatide was generally well tolerated with no new safety signals during the OLE
PK supports once-weekly... More
